Bio-Rad Laboratories is in talks to combine with Germany-based life-sciences company Qiagen in a potential $10 billion deal, WSJ reported citing sources. California-based Bio-Rad, manufacturer of life-science research and clinical diagnostics products, has a market-cap of $12.85 billion. The talks have been going on for a while but an agreement is unlikely for another few weeks, the report added.